Bladder Carcinoma Clinical Trials

This research study is for people with advanced liver cancer who have never received systemic medicine (affecting the entire body) for advanced liver cancer. This is a randomized, open-label Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib can slow the progression of ...

This clinical study evaluates the efficacy and safety of regorafenib in patients with advanced liver cancer who have progressed on sorafenib treatment. Approximately 560 patients who meet the entry criteria will be randomly assigned in a 2:1 ratio to regorafenib or placebo (1/3 chance to receive placebo). Primary endpoint of ...

This is a randomized trial to evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib once daily in subjects with unresectable advanced or metastatic Child-Pugh A HCC. Patients who are candidates for potentially ...

Because of the high risk for development of muscle invasive disease, cystectomy is recommended for CIS, high-grade Ta and T1 patients who experience disease recurrence following intravesical therapy. Vicinium is an experimental agent that may provide an alternative to cystectomy.

- This is the first study where BAY1163877 is given to humans. Impact of the study is to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme ...

A Humanitarian Use Device trial for patients who have hepatocellular carcinoma of the liver.

A research study is collecting blood samples to better understand biomarkers in adults recently diagnosed with or at risk for developing Hepatocellular Carcinoma (HCC). Those with hepatitis B or C, nonalcoholic steatohepatitis (NASH), cirrhosis or other forms of liver disease may be at risk.

A research study is evaluating an investigational medication used in combination with Nivolumab (OPDIVO®) in those diagnosed with Muscle-Invasive Urothelial Carcinoma of the bladder.  

The FIERCE-22 study is a Phase 1b/2 study to evaluate the effectiveness and safety of vofatamab (B-701) in combination with the immunotherapy drug pembrolizumab in the treatment of subjects with Stage IV, locally advanced or metastatic FGFR3 wild-type (WT) or mutation positive UCC who have previously been treated with a ...

Patients who wish to enroll in a research study should discuss the possibilities with their urologist. The TUCC Clinical Research Department staff remains in constant communication with patients throughout their enrollment in clinical trials. These patients receive all study related medication and procedures at no cost. Participation is voluntary and ...